Search Results - "Ballinger, Marcus"

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

“…Summary Background Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death…”
Get full text

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics by Seymour, Lesley, Prof, Bogaerts, Jan, PhD, Perrone, Andrea, MD, Ford, Robert, MD, Schwartz, Lawrence H, Prof, Mandrekar, Sumithra, Prof, Lin, Nancy U, MD, Litière, Saskia, PhD, Dancey, Janet, Prof, Chen, Alice, MD, Hodi, F Stephen, Prof, Therasse, Patrick, MD, Hoekstra, Otto S, Prof, Shankar, Lalitha K, MD, Wolchok, Jedd D, MD, Ballinger, Marcus, PhD, Caramella, Caroline, MD, de Vries, Elisabeth G E, Prof

“…Summary Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour…”
Get full text

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer by Patil, Namrata S., Nabet, Barzin Y., Müller, Sören, Koeppen, Hartmut, Zou, Wei, Giltnane, Jennifer, Au-Yeung, Amelia, Srivats, Shyam, Cheng, Jason H., Takahashi, Chikara, de Almeida, Patricia E., Chitre, Avantika S., Grogan, Jane L., Rangell, Linda, Jayakar, Sangeeta, Peterson, Maureen, Hsia, Allison W., O’Gorman, William E., Ballinger, Marcus, Banchereau, Romain, Shames, David S.

“…Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their…”
Get full text

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy by Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D

“…Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately…”
Get full text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial by Rittmeyer, Achim, MD, Barlesi, Fabrice, PhD, Waterkamp, Daniel, MD, Park, Keunchil, MD, Ciardiello, Fortunato, MD, von Pawel, Joachim, MD, Gadgeel, Shirish M, MD, Hida, Toyoaki, PhD, Kowalski, Dariusz M, PhD, Dols, Manuel Cobo, MD, Cortinovis, Diego L, PhD, Leach, Joseph, MD, Polikoff, Jonathan, MD, Barrios, Carlos, MD, Kabbinavar, Fairooz, MD, Frontera, Osvaldo Arén, MD, De Marinis, Filippo, MD, Turna, Hande, MD, Lee, Jong-Seok, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, He, Pei, PhD, Chen, Daniel S, MD, Sandler, Alan, MD, Gandara, David R, Dr

“…Summary Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and…”
Get full text

MOSBY enables multi-omic inference and spatial biomarker discovery from whole slide images by Şenbabaoğlu, Yasin, Prabhakar, Vignesh, Khormali, Aminollah, Eastham, Jeff, Liu, Evan, Warner, Elisa, Nabet, Barzin, Srivastava, Minu, Ballinger, Marcus, Liu, Kai

“…The utility of deep neural nets has been demonstrated for mapping hematoxylin-and-eosin (H&E) stained image features to expression of individual genes…”
Get full text

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1) by Wu, Benjamin, Sternheim, Nitzan, Agarwal, Priya, Suchomel, Julia, Vadhavkar, Shweta, Bruno, Rene, Ballinger, Marcus, Bernaards, Coen A., Chan, Phyllis, Ruppel, Jane, Jin, Jin, Girish, Sandhya, Joshi, Amita, Quarmby, Valerie

“…Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on…”
Get full text

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients by Patil, Namrata S, Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S

“…Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum…”
Get full text

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment by Fehlings, Michael, Jhunjhunwala, Suchit, Kowanetz, Marcin, O’Gorman, William E., Hegde, Priti S., Sumatoh, Hermi, Lee, Boon Heng, Nardin, Alessandra, Becht, Etienne, Flynn, Susan, Ballinger, Marcus, Newell, Evan W., Yadav, Mahesh

“…BackgroundThere is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize…”
Get full text

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) by Peters, Solange, Galle, Peter R., Bernaards, Coen A., Ballinger, Marcus, Bruno, René, Quarmby, Valerie, Ruppel, Jane, Vilimovskij, Alexandr, Wu, Benjamin, Sternheim, Nitzan, Reck, Martin

“…Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate…”
Get full text

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial by Gadgeel, Shirish, Hirsch, Fred R., Kerr, Keith, Barlesi, Fabrice, Park, Keunchil, Rittmeyer, Achim, Zou, Wei, Bhatia, Namrata, Koeppen, Hartmut, Paul, Sarah M., Shames, David, Yi, Jing, Matheny, Christina, Ballinger, Marcus, McCleland, Mark, Gandara, David R.

“…•OAK subgroup analysis compared SP142 and 22C3 assays at defined programmed death ligand 1 thresholds.•Survival benefit of atezolizumab over docetaxel across…”
Get full text

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework by Chan, Phyllis, Marchand, Mathilde, Yoshida, Kenta, Vadhavkar, Shweta, Wang, Nina, Lin, Alyse, Wu, Benjamin, Ballinger, Marcus, Sternheim, Nitzan, Jin, Jin Y., Bruno, René

“…The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth…”
Get full text

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model by VanderPorten, Erica C, Taverna, Pietro, Hogan, Jennifer N, Ballinger, Marcus D, Flanagan, W Michael, Fucini, Raymond V

“…Aurora kinases play key roles in regulating centrosome maturation, mitotic spindle formation, and cytokinesis during cell division, and are considered…”
Get full text

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel by Gandara, David, Reck, Martin, Moro-Sibilot, Denis, Mazieres, Julien, Gadgeel, Shirish, Morris, Stefanie, Cardona, Andres, Mendus, Diana, Ballinger, Marcus, Rittmeyer, Achim, Peters, Solange

“…BackgroundTreatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in…”
Get full text

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial by Zhou, Caicun, Srivastava, Minu K, Xu, Hao, Felip, Enriqueta, Wakelee, Heather, Altorki, Nasser, Reck, Martin, Liersch, Rüdiger, Kryzhanivska, Anna, Oizumi, Satoshi, Tanaka, Hiroshi, Hamm, John, McCune, Steven L, Bennett, Elizabeth, Gitlitz, Barbara, McNally, Virginia, Ballinger, Marcus, McCleland, Mark, Zou, Wei, Das Thakur, Meghna, Novello, Silvia

“…BackgroundTumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA…”
Get full text

601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC by Lu, Tianshi, Socinski, Mark A, Reck, Martin, West, Howard, Cappuzzo, Federico, Barlesi, Fabrice, Jotte, Robert M, Müller, Sören, Hamidi, Habib, Amitai, Assaf, Koeppen, Hartmut, Shames, David S, Ballinger, Marcus, Qamra, Aditi, Srivastava, Minu K, Nabet, Barzin

“…BackgroundThe phase 3 IMpower150 trial showed significantly improved progression-free survival (PFS) and overall survival (OS) with atezolizumab plus…”
Get full text

606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy by Srivastava, Minu K, Gayevskiy, Velimir, Ma, Vy, Estay, Ivette, Rodas, Miguel Lopez de, Rajendran, Barani Kumar, Hoang, Tien, Ballinger, Marcus, Amin, Reena, Herbst, Roy S, Marinis, Filippo de, Giaccone, Giuseppe, Jassem, Jacek, Spigel, David R, Schalper, Kurt, Koeppen, Hartmut, Shames, David S, Johnston, Robert, Giltnane, Jennifer M, Nabet, Barzin Y

“…BackgroundThe presence of TLS in tumor tissues is associated with good prognosis and increased immunotherapy sensitivity across several cancers. In an analysis…”
Get full text

Fragment-Based Discovery of Nonpeptidic BACE-1 Inhibitors Using Tethering by Yang, Wenjin, Fucini, Raymond V, Fahr, Bruce T, Randal, Mike, Lind, Kenneth E, Lam, Melissa B, Lu, Wanli, Lu, Yafan, Cary, Douglas R, Romanowski, Michael J, Colussi, Dennis, Pietrak, Beth, Allison, Timothy J, Munshi, Sanjeev K, Penny, David M, Pham, Phuongly, Sun, Jian, Thomas, Anila E, Wilkinson, Jennifer M, Jacobs, Jeffrey W, McDowell, Robert S, Ballinger, Marcus D

“…BACE-1 (β-site amyloid precursor protein cleaving enzyme), a prominent target in Alzheimer’s disease drug discovery efforts, was surveyed using Tethering…”
Get full text

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) by Spira, Alexander I., Park, Keunchil, Mazières, Julien, Vansteenkiste, Johan F., Rittmeyer, Achim, Ballinger, Marcus, Waterkamp, Daniel, Kowanetz, Marcin, Mokatrin, Ahmad, Fehrenbacher, Louis

“…Abstract only…”
Get full text

Aminoethylenes:  A Tetrahedral Intermediate Isostere Yielding Potent Inhibitors of the Aspartyl Protease BACE-1 by Yang, Wenjin, Lu, Wanli, Lu, Yafan, Zhong, Min, Sun, Jian, Thomas, Anila E, Wilkinson, Jennifer M, Fucini, Raymond V, Lam, Melissa, Randal, Mike, Shi, Xiao-Ping, Jacobs, Jeffrey W, McDowell, Robert S, Gordon, Eric M, Ballinger, Marcus D

“…A series of novel β-site amyloid precursor protein cleaving enzyme (BACE-1) inhibitors containing an aminoethylene (AE) tetrahedral intermediate isostere were…”
Get full text